Developer docs
API playgroundTry for free, no card

Search company profiles

Telix Pharmaceuticals

Full company profile

uuid0000dtw

Namestring
Telix Pharmaceuticals
Legal namestring
Telix Pharmaceuticals Limited
Websiteurl
telixpharma.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Telix Pharmaceuticals Limited is a global, commercial-stage biopharmaceutical company headquartered in North Melbourne, Australia, and dual-listed on the ASX and NASDAQ under the ticker TLX. The company develops and commercializes theranostic radiopharmaceuticals — molecularly targeted diagnostic imaging agents paired with matched therapeutic radioligands — with a disease focus on urologic oncology (prostate, kidney), neuro-oncology (glioma, glioblastoma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. The commercial core is the PSMA-PET imaging franchise, anchored by Illuccix (kit for preparation of gallium-68 gozetotide injection, approved by FDA, TGA, and Health Canada, plus 19 European markets via DCP) and its next-generation successor Gozellix, which launched in the U.S. in 2025 with permanent HCPCS code A9616 and CMS Transitional Pass-Through status.

Short descriptiontext

Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company that develops and commercializes theranostic radiopharmaceuticals (diagnostic imaging agents and matched therapeutic radioligands), anchored by FDA- and EMA-approved PSMA-PET imaging agents Illuccix and Gozellix for prostate cancer, serving hospitals, nuclear medicine departments, and urology clinics worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersNorth Melbourne, Australia
HQ citystring
North Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
theranostic radiopharmaceuticals, diagnostic imaging agents, cancer radioligand therapy, PSMA-PET imaging, radiopharmacy distribution
Industry10 codes
PRIMARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAE
Radiopharmacy Compounding & Dispensing (Hospital/Commercial)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLALAGAH
Oncology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAGAI
Nuclear Medicine Clinical Services & Therapy Centers
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAE
Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Diagnostic Imaging Centers621512
  • Medical and Diagnostic Laboratories62151
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Radiopharmaceuticals
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model5 records
1Commercial product sales (Precision Medicine)
TypeHardware Sales
Description

Sales of FDA/TGA/Health Canada-approved PSMA-PET imaging agents Illuccix and Gozellix, plus newer launches of Zircaix and Pixclara (subject to approval), generating FY2025 Precision Medicine revenue of approximately $622 million with 22% YoY growth. Pricing is per unit dose (kit for preparation of gallium-68 gozetotide injection).

seekingalpha.com
2Third-party radiopharmacy distribution (RLS)
TypeManaged Services
Description

Revenue from the RLS Radiopharmacies network acquired January 2025, providing third-party PET/SPECT product sales and distribution service fees. Q3 2025 RLS third-party revenue was $47M; Q2 2025 was $46M. RLS revenue excludes Illuccix/Gozellix product sales.

telixpharma.com
3Strategic collaboration milestones and royalties
TypeLicensing Royalties
Description

Telix is eligible to receive up to $2.1 billion in aggregate development and commercial milestone payments plus low double-digit royalties from its Regeneron collaboration (April 2026). Regeneron paid $40M upfront for access to four initial therapeutic programs with options to expand to eight programs under a 50/50 cost/profit share.

globenewswire.com
4Future therapeutic product sales (pipeline)
TypeHardware Sales
Description

Anticipated revenue from therapeutic radioligand product launches (e.g., TLX591-Tx for mCRPC, TLX101-Tx for glioblastoma, TLX250-Tx for ccRCC, TLX597-Tx next-gen RLT). Management expects first therapeutic commercial launch in 2028.

heidelberg-pharma.com
5Convertible bond financing
TypeSubscription Recurring
Description

Telix raised US$600 million in 1.50% convertible notes due 2031 (upsized from $550M) in April 2026, with a 37.5% conversion premium. Proceeds used to repurchase A$637M of existing A$650M convertible bonds due 2029. An earlier A$600M convertible bond offering was completed in July 2024.

prnewswire.com
Cost components6 values
Supply Chain, Technology or R&D, Operations, Marketing or Sales, Personnel, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 11 records shown
1Illuccix
Description

First-generation PSMA-PET imaging agent (kit for the preparation of gallium-68 gozetotide injection) for detection and localization of PSMA-positive lesions in men with prostate cancer; approved by TGA, FDA, Health Canada, BASG (Austria), AEMPS (Spain), BfArM (Germany), AFMPS (Belgium), AIFA (Italy), and 19 European markets.

telixpharma.com
+10 more records
Core offering1 text field

Telix Pharmaceuticals develops and commercializes therapeutic and diagnostic ("theranostic") radiopharmaceuticals for oncology and rare diseases. Its commercial core is the FDA-approved PSMA-PET imaging franchise of Illuccix and Gozellix (gallium-68 gozetotide kits for prostate cancer imaging), supported by Telix Manufacturing Solutions (TMS) and a late-stage pipeline of radioligand therapies (e.g., TLX591-Tx, TLX101-Tx, TLX250-Tx), imaging agents (Pixclara, Zircaix), the SENSEI drop-in gamma probe, and QDOSE dosimetry software.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company that operates a vertically integrated theranostic radiopharmaceutical platform spanning therapeutic and diagnostic ('theranostics') products. The portfolio architecture is a platform-plus-modules model: the lead commercial PSMA-PET imaging franchise includes Illuccix® (kit for the preparation of gallium-68 gozetotide injection) and its next-generation successor Gozellix®, both approved in the U.S. and key European markets, forming the Precision Medicine commercial core. These are supported by Telix Manufacturing Solutions (TMS) — a network of radiopharmacies (RLS), production facilities, and cyclotrons across the U.S. (Sacramento, North Melbourne-equivalent), Belgium (Brussels South/Seneffe), Japan (Yokohama), and Australia — together with the ARTMS QUANTM Irradiation System (QIS), IBA Cyclone KIUBE cyclotrons, and GE FASTlab production technology. The investigational imaging pipeline adds TLX101-Px (Pixclara®/Pixlumi®, 18F-FET for glioma), TLX250-Px (Zircaix®, 89Zr-girentuximab for kidney cancer), and the AlFluor™ radiochemistry platform. The therapeutic pipeline is anchored by TLX591-Tx (ProstACT Global Phase 3 lutetium-177 rosopatamab tetraxetan for mCRPC), TLX597-Tx (next-gen PSMA RLT in OPTIMAL-PSMA Phase 2), TLX101-Tx (131I-iodofalan for glioblastoma in IPAX-BrIGHT Phase 3), TLX250-Tx (177Lu-DOTA-girentuximab for ccRCC, LUTEON/STARLITE-1), TLX252 (225Ac-DOTA-girentuximab targeted alpha therapy), TLX090 (153Sm-DOTMP for bone pain, SOLACE Phase 1), TLX592 (225Ac-PSMA-RADmAb), and TLX400 (FAP-targeting therapy). Adjacent medical-technology and software modules include the SENSEI® drop-in gamma probe (for robotic-assisted radio-guided surgery) and QDOSE® dosimetry software (510(k)-cleared, CE-marked, MDR-certified). Regeneron partnership (April 2026) added a 50/50 cost- and profit-sharing program structure on up to eight solid-tumor radiopharmaceutical programs, and the United Imaging collaboration (June 2026) integrates Telix's imaging agents with United Imaging's scanners and AI. AI-enabled PSMA-PET work is conducted via the PROMISE-PET registry collaboration with University Hospital Essen.

Product and service15 records
1Illuccix®
CategoryDiagnostic imaging agent (PSMA-PET)
Description

Telix's lead PSMA-PET imaging agent (kit for the preparation of gallium-68 gozetotide injection) for detection and localization of PSMA-positive lesions in adults with prostate cancer, approved by the FDA and TGA in the United States and Australia and rolled out across European markets.

2Gozellix®
CategoryDiagnostic imaging agent (PSMA-PET)
Description

Next-generation PSMA-PET imaging agent (kit for the preparation of gallium-68 (68Ga) gozetotide injection) for prostate cancer, offering up to 6-hour shelf life, scalable production via gallium generators or cyclotron-based methods, and full CMS reimbursement with permanent HCPCS Level II code A9616 and TPT status.

3TLX101-Px (Pixclara®)
CategoryInvestigational imaging agent (glioma)
Description

Investigational PET imaging agent (Floretyrosine F 18 / 18F-FET) for the imaging and characterization of recurrent or progressive glioma in adult and pediatric patients, with Orphan Drug and Fast Track designations from the FDA; targets LAT1 and LAT2 membrane transport proteins. EU brand: Pixlumi®.

4TLX250-Px (Zircaix®)
CategoryInvestigational imaging agent (kidney cancer)
Description

Kidney cancer imaging agent (89Zr-DFO-girentuximab, TLX250-CDx) PET/CT for characterization of renal malignancies including clear cell renal cell carcinoma (ccRCC). BLA under review with FDA.

5TLX591-Tx (177Lu-rosopatamab tetraxetan)
CategoryInvestigational radioligand therapy (prostate cancer)
Description

PSMA-targeted lutetium-177 radio antibody-drug conjugate (rADC) therapy candidate for metastatic castration-resistant prostate cancer (mCRPC). ProstACT Global Phase 3 study Part 1 met primary safety/tolerability objectives; Part 2 expansion underway targeting approximately 490 patients.

6TLX597-Tx
CategoryInvestigational radioligand therapy (prostate cancer)
Description

Next-generation PSMA-targeting radioligand therapy candidate for prostate cancer being developed to improve patient access to lutetium therapy. OPTIMAL-PSMA Phase 2 trial dosimetry data presented at IPCS 2026 showed low salivary gland and kidney uptake, supporting dose intensification. OPTIMAL-E Phase 2 in mHSPC initiating.

7TLX250-Tx (177Lu-DOTA-girentuximab)
CategoryInvestigational radioligand therapy (kidney cancer)
Description

Investigational 177Lu-DOTA-girentuximab radioligand therapy for clear cell renal cell carcinoma (ccRCC). Pivotal LUTEON trial approved in Australia as monotherapy in advanced metastatic ccRCC. STARLITE-1 Phase 1b/2 trial investigating combination with cabozantinib and nivolumab.

8TLX090 (153Sm-DOTMP)
CategoryInvestigational radioligand therapy (bone pain palliation)
Description

Therapeutic radiopharmaceutical candidate (Samarium-153-DOTMP) for the palliation of bone pain in patients with osteoblastic metastatic disease. Phase 1 SOLACE trial first patient dosed October 2025. Acquired via QSAM Biosciences acquisition.

9TLX592 (225Ac-PSMA-RADmAb)
CategoryInvestigational targeted alpha therapy (prostate cancer)
Description

Investigational targeted alpha therapy (Actinium-225 labeled PSMA radio antibody) for advanced metastatic castration-resistant prostate cancer. HREC application submitted in Australia for Phase 1 first-in-human therapeutic study.

10TLX400 (177Lu-DOTAGA.Glu.(FAPi)2)
CategoryInvestigational radioligand therapy (FAP-targeting)
Description

Fibroblast Activation Protein (FAP)-targeting radioligand therapy candidate in-licensed by Telix in March 2025. Demonstrated clinical antitumor activity and manageable safety in advanced sarcoma patients in Journal of Nuclear Medicine publication. Differentiated by novel structure for prolonged tumor retention.

11TLX252 (225Ac-DOTA-girentuximab)
CategoryInvestigational targeted alpha therapy (renal cancer)
Description

Actinium-225 labeled CAIX-targeting investigational therapy for renal cancer. Being investigated in syngeneic murine tumor models and combined with DNA damage response inhibitors and immune checkpoint inhibitors in CAIX-positive renal cancer.

12SENSEI® drop-in gamma probe
CategoryMedical device (radio-guided surgery)
Description

Miniature drop-in gamma probe technology designed specifically for robotic-assisted surgery, registered with the Australian TGA, the U.S. FDA, and has CE Mark for use in the European Economic Area. Used with radiotracers to identify cancer deposits and occult lymph nodes. Acquired via Lightpoint Medical acquisition.

13QDOSE® dosimetry software
CategoryMedical software (radiopharmaceutical dosimetry)
Description

Dosimetry software with 510(k) clearance from the FDA, CE-marked and Medical Device Regulation (MDR) certified for clinical use within the European Union (EU). Used in nuclear medicine dosimetry workflows.

14AlFluor™ radiochemistry platform
CategoryRadiochemistry platform technology
Description

Novel PET radiochemistry solution based on 18F-aluminium fluoride (AlF) launched by Telix Precision Medicine. Enables flexible radiolabeling of PSMA with either AlF or gallium-68 (68Ga). Includes strategic agreement with University Hospital Ghent and Ghent University for [18F]AlF-PSMA-11.

15Scintimun®
CategoryDiagnostic imaging product
Description

Telix diagnostic imaging product referenced as part of the company's commercial and late-stage precision medicine products portfolio.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Novartis is the dominant player in radioligand therapy with Pluvicto (lutetium-177 vipivotide tetraxetan) for mCRPC and Lutathera for neuroendocrine tumors. As a large-cap incumbent, Novartis competes directly with Telix's PSMA-targeted therapeutic pipeline (TLX591-Tx, TLX597-Tx) and has first-mover advantage in the commercial radioligand therapy market.

TypeBroad incumbent
Description

GE HealthCare is a broad incumbent in molecular imaging, manufacturing PET scanners (including the GE FASTlab production platform used by Telix for Gozellix), radiopharmaceuticals, and contrast media. As a diversified imaging and diagnostics major, it overlaps with Telix across the imaging value chain.

TypeDirect peer
Description

Curium is a global radiopharmaceutical manufacturer and distributor that competes directly with Telix in nuclear medicine imaging agents and operates a vertically integrated production and distribution model similar to Telix Manufacturing Solutions (TMS) and RLS Radiopharmacies.

TypeDirect peer
Description

Lantheus is a direct competitor in PSMA-PET imaging with Pylarify (piflufolastat F-18) approved for prostate cancer. Both companies target the same indication with similar radiopharmaceutical imaging agents and compete for hospital and urology clinic accounts in the U.S. and Europe.

TypeDirect peer
Description

ITM is a direct peer in radioligand therapy with a pipeline of lutetium-177-based targeted radionuclide therapies for solid tumors. ITM also operates as a manufacturer of medical isotopes, competing with Telix on supply chain and pipeline assets in the radiopharmaceutical theranostics space.

TypeBroad incumbent
Description

Siemens Healthineers is a broad incumbent in medical imaging and radiation oncology (via Varian), with a strategic clinical collaboration announced with Telix in December 2025. It overlaps with Telix across PET imaging hardware, radiopharmacy, and radiation therapy—adjacent rather than direct competition.

TypeBroad incumbent
Description

Bayer is a broad incumbent in radiopharmaceuticals with Xofigo (radium-223) for bone metastases in prostate cancer and an active radioligand therapy pipeline. Bayer competes with Telix in the prostate cancer theranostics space and is developing next-generation targeted radiopharmaceuticals.

8Telix Pharmaceuticals (acquired by AstraZeneca: Fusion Pharmaceuticals)
TypeEmerging player
Description

Fusion Pharmaceuticals (acquired by AstraZeneca) is an emerging player in targeted alpha therapies using actinium-225, directly comparable to Telix's TLX252 and TLX592 alpha-emitting programs. Both companies pursued radiopharmaceutical conjugates for solid tumors before their respective strategic transactions.

TypeOthers
Description

Cardinal Health is a commercial radiopharmacy distribution partner (supplies finished unit doses of Gozellix to U.S. customers) and operates its own radiopharmaceutical distribution network. While primarily a logistics partner, it is an adjacent participant in the U.S. nuclear medicine supply chain.

TypeBroad incumbent
Description

Bracco Imaging is a broad incumbent in diagnostic imaging agents and contrast media with a growing radiopharmaceutical portfolio. It competes with Telix in the broader molecular imaging market and has infrastructure for nuclear medicine distribution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A12 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Telix Pharmaceuticals

Radiopharmaceuticalstelixpharma.com

Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company that develops and commercializes theranostic radiopharmaceuticals (diagnostic imaging agents and matched therapeutic radioligands), anchored by FDA- and EMA-approved PSMA-PET imaging agents Illuccix and Gozellix for prostate cancer, serving hospitals, nuclear medicine departments, and urology clinics worldwide.

What Telix Pharmaceuticals does

Telix Pharmaceuticals Limited is a global, commercial-stage biopharmaceutical company headquartered in North Melbourne, Australia, and dual-listed on the ASX and NASDAQ under the ticker TLX. The company develops and commercializes theranostic radiopharmaceuticals — molecularly targeted diagnostic imaging agents paired with matched therapeutic radioligands — with a disease focus on urologic oncology (prostate, kidney), neuro-oncology (glioma, glioblastoma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. The commercial core is the PSMA-PET imaging franchise, anchored by Illuccix (kit for preparation of gallium-68 gozetotide injection, approved by FDA, TGA, and Health Canada, plus 19 European markets via DCP) and its next-generation successor Gozellix, which launched in the U.S. in 2025 with permanent HCPCS code A9616 and CMS Transitional Pass-Through status.

Telix Pharmaceuticals firmographics

Firmographics
Name
Telix Pharmaceuticals
Legal name
Telix Pharmaceuticals Limited
Website
https://telixpharma.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company that develops and commercializes theranostic radiopharmaceuticals (diagnostic imaging agents and matched therapeutic radioligands), anchored by FDA- and EMA-approved PSMA-PET imaging agents Illuccix and Gozellix for prostate cancer, serving hospitals, nuclear medicine departments, and urology clinics worldwide.
Ownership category
akta.pro rank

Telix Pharmaceuticals industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Diagnostic Imaging Centers (621512), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAE
Radiopharmacy Compounding & Dispensing (Hospital/Commercial)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLALAGAH
Oncology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAGAI
Nuclear Medicine Clinical Services & Therapy Centers
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAE
Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

Keywords

  • Theranostic radiopharmaceuticals
  • Diagnostic imaging agents
  • Cancer radioligand therapy
  • PSMA-PET imaging
  • Radiopharmacy distribution

Where Telix Pharmaceuticals is headquartered

Location

Headquarters

HQ city
North Melbourne
HQ country
Australia
HQ region
Oceania

Markets served

Telix Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Operations, Marketing or Sales, Personnel, Infrastructure

Revenue model

  1. Commercial product sales (Precision Medicine): Sales of FDA/TGA/Health Canada-approved PSMA-PET imaging agents Illuccix and Gozellix, plus newer launches of Zircaix and Pixclara (subject to approval), generating FY2025 Precision Medicine revenue of approximately $622 million with 22% YoY growth. Pricing is per unit dose (kit for preparation of gallium-68 gozetotide injection).
  2. Third-party radiopharmacy distribution (RLS): Revenue from the RLS Radiopharmacies network acquired January 2025, providing third-party PET/SPECT product sales and distribution service fees. Q3 2025 RLS third-party revenue was $47M; Q2 2025 was $46M. RLS revenue excludes Illuccix/Gozellix product sales.
  3. Strategic collaboration milestones and royalties: Telix is eligible to receive up to $2.1 billion in aggregate development and commercial milestone payments plus low double-digit royalties from its Regeneron collaboration (April 2026). Regeneron paid $40M upfront for access to four initial therapeutic programs with options to expand to eight programs under a 50/50 cost/profit share.
  4. Future therapeutic product sales (pipeline): Anticipated revenue from therapeutic radioligand product launches (e.g., TLX591-Tx for mCRPC, TLX101-Tx for glioblastoma, TLX250-Tx for ccRCC, TLX597-Tx next-gen RLT). Management expects first therapeutic commercial launch in 2028.
  5. Convertible bond financing: Telix raised US$600 million in 1.50% convertible notes due 2031 (upsized from $550M) in April 2026, with a 37.5% conversion premium. Proceeds used to repurchase A$637M of existing A$650M convertible bonds due 2029. An earlier A$600M convertible bond offering was completed in July 2024.

Go-to-market motion4 records

Telix Pharmaceuticals product offering

Product offering

Core offering

Telix Pharmaceuticals develops and commercializes therapeutic and diagnostic ("theranostic") radiopharmaceuticals for oncology and rare diseases. Its commercial core is the FDA-approved PSMA-PET imaging franchise of Illuccix and Gozellix (gallium-68 gozetotide kits for prostate cancer imaging), supported by Telix Manufacturing Solutions (TMS) and a late-stage pipeline of radioligand therapies (e.g., TLX591-Tx, TLX101-Tx, TLX250-Tx), imaging agents (Pixclara, Zircaix), the SENSEI drop-in gamma probe, and QDOSE dosimetry software.

Product overview

Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company that operates a vertically integrated theranostic radiopharmaceutical platform spanning therapeutic and diagnostic ('theranostics') products. The portfolio architecture is a platform-plus-modules model: the lead commercial PSMA-PET imaging franchise includes Illuccix® (kit for the preparation of gallium-68 gozetotide injection) and its next-generation successor Gozellix®, both approved in the U.S. and key European markets, forming the Precision Medicine commercial core. These are supported by Telix Manufacturing Solutions (TMS) — a network of radiopharmacies (RLS), production facilities, and cyclotrons across the U.S. (Sacramento, North Melbourne-equivalent), Belgium (Brussels South/Seneffe), Japan (Yokohama), and Australia — together with the ARTMS QUANTM Irradiation System (QIS), IBA Cyclone KIUBE cyclotrons, and GE FASTlab production technology. The investigational imaging pipeline adds TLX101-Px (Pixclara®/Pixlumi®, 18F-FET for glioma), TLX250-Px (Zircaix®, 89Zr-girentuximab for kidney cancer), and the AlFluor™ radiochemistry platform. The therapeutic pipeline is anchored by TLX591-Tx (ProstACT Global Phase 3 lutetium-177 rosopatamab tetraxetan for mCRPC), TLX597-Tx (next-gen PSMA RLT in OPTIMAL-PSMA Phase 2), TLX101-Tx (131I-iodofalan for glioblastoma in IPAX-BrIGHT Phase 3), TLX250-Tx (177Lu-DOTA-girentuximab for ccRCC, LUTEON/STARLITE-1), TLX252 (225Ac-DOTA-girentuximab targeted alpha therapy), TLX090 (153Sm-DOTMP for bone pain, SOLACE Phase 1), TLX592 (225Ac-PSMA-RADmAb), and TLX400 (FAP-targeting therapy). Adjacent medical-technology and software modules include the SENSEI® drop-in gamma probe (for robotic-assisted radio-guided surgery) and QDOSE® dosimetry software (510(k)-cleared, CE-marked, MDR-certified). Regeneron partnership (April 2026) added a 50/50 cost- and profit-sharing program structure on up to eight solid-tumor radiopharmaceutical programs, and the United Imaging collaboration (June 2026) integrates Telix's imaging agents with United Imaging's scanners and AI. AI-enabled PSMA-PET work is conducted via the PROMISE-PET registry collaboration with University Hospital Essen.

Differentiator

Problem solved

Functional benefit

Brands

  • Illuccix: First-generation PSMA-PET imaging agent (kit for the preparation of gallium-68 gozetotide injection) for detection and localization of PSMA-positive lesions in men with prostate cancer; approved by TGA, FDA, Health Canada, BASG (Austria), AEMPS (Spain), BfArM (Germany), AFMPS (Belgium), AIFA (Italy), and 19 European markets.
  • Gozellix
  • Zircaix
  • Pixclara
  • Pixlumi
  • SENSEI
  • QDOSE
  • AlFluor
  • Telix Manufacturing Solutions (TMS)
  • ARTMS QUANTM Irradiation System (QIS)
  • Scintimun

Products and services

  • Illuccix® Telix's lead PSMA-PET imaging agent (kit for the preparation of gallium-68 gozetotide injection) for detection and localization of PSMA-positive lesions in adults with prostate cancer, approved by the FDA and TGA in the United States and Australia and rolled out across European markets.
  • Gozellix® Next-generation PSMA-PET imaging agent (kit for the preparation of gallium-68 (68Ga) gozetotide injection) for prostate cancer, offering up to 6-hour shelf life, scalable production via gallium generators or cyclotron-based methods, and full CMS reimbursement with permanent HCPCS Level II code A9616 and TPT status.
  • TLX101-Px (Pixclara®) Investigational PET imaging agent (Floretyrosine F 18 / 18F-FET) for the imaging and characterization of recurrent or progressive glioma in adult and pediatric patients, with Orphan Drug and Fast Track designations from the FDA; targets LAT1 and LAT2 membrane transport proteins. EU brand: Pixlumi®.
  • TLX250-Px (Zircaix®) Kidney cancer imaging agent (89Zr-DFO-girentuximab, TLX250-CDx) PET/CT for characterization of renal malignancies including clear cell renal cell carcinoma (ccRCC). BLA under review with FDA.
  • TLX591-Tx (177Lu-rosopatamab tetraxetan) PSMA-targeted lutetium-177 radio antibody-drug conjugate (rADC) therapy candidate for metastatic castration-resistant prostate cancer (mCRPC). ProstACT Global Phase 3 study Part 1 met primary safety/tolerability objectives; Part 2 expansion underway targeting approximately 490 patients.
  • TLX597-Tx Next-generation PSMA-targeting radioligand therapy candidate for prostate cancer being developed to improve patient access to lutetium therapy. OPTIMAL-PSMA Phase 2 trial dosimetry data presented at IPCS 2026 showed low salivary gland and kidney uptake, supporting dose intensification. OPTIMAL-E Phase 2 in mHSPC initiating.
  • TLX250-Tx (177Lu-DOTA-girentuximab) Investigational 177Lu-DOTA-girentuximab radioligand therapy for clear cell renal cell carcinoma (ccRCC). Pivotal LUTEON trial approved in Australia as monotherapy in advanced metastatic ccRCC. STARLITE-1 Phase 1b/2 trial investigating combination with cabozantinib and nivolumab.
  • TLX090 (153Sm-DOTMP) Therapeutic radiopharmaceutical candidate (Samarium-153-DOTMP) for the palliation of bone pain in patients with osteoblastic metastatic disease. Phase 1 SOLACE trial first patient dosed October 2025. Acquired via QSAM Biosciences acquisition.
  • TLX592 (225Ac-PSMA-RADmAb) Investigational targeted alpha therapy (Actinium-225 labeled PSMA radio antibody) for advanced metastatic castration-resistant prostate cancer. HREC application submitted in Australia for Phase 1 first-in-human therapeutic study.
  • TLX400 (177Lu-DOTAGA.Glu.(FAPi)2) Fibroblast Activation Protein (FAP)-targeting radioligand therapy candidate in-licensed by Telix in March 2025. Demonstrated clinical antitumor activity and manageable safety in advanced sarcoma patients in Journal of Nuclear Medicine publication. Differentiated by novel structure for prolonged tumor retention.
  • TLX252 (225Ac-DOTA-girentuximab) Actinium-225 labeled CAIX-targeting investigational therapy for renal cancer. Being investigated in syngeneic murine tumor models and combined with DNA damage response inhibitors and immune checkpoint inhibitors in CAIX-positive renal cancer.
  • SENSEI® drop-in gamma probe Miniature drop-in gamma probe technology designed specifically for robotic-assisted surgery, registered with the Australian TGA, the U.S. FDA, and has CE Mark for use in the European Economic Area. Used with radiotracers to identify cancer deposits and occult lymph nodes. Acquired via Lightpoint Medical acquisition.
  • QDOSE® dosimetry software Dosimetry software with 510(k) clearance from the FDA, CE-marked and Medical Device Regulation (MDR) certified for clinical use within the European Union (EU). Used in nuclear medicine dosimetry workflows.
  • AlFluor™ radiochemistry platform Novel PET radiochemistry solution based on 18F-aluminium fluoride (AlF) launched by Telix Precision Medicine. Enables flexible radiolabeling of PSMA with either AlF or gallium-68 (68Ga). Includes strategic agreement with University Hospital Ghent and Ghent University for [18F]AlF-PSMA-11.
  • Scintimun® Telix diagnostic imaging product referenced as part of the company's commercial and late-stage precision medicine products portfolio.

Companies that use Telix Pharmaceuticals

Customer profile

Ideal customer profiles3 records

Telix Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability6 records

Feature10 records

Telix Pharmaceuticals partnerships and signals

Strategic signal

Recent moves11 records

Expansion highlights7 records

Telix Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Novartis is the dominant player in radioligand therapy with Pluvicto (lutetium-177 vipivotide tetraxetan) for mCRPC and Lutathera for neuroendocrine tumors. As a large-cap incumbent, Novartis competes directly with Telix's PSMA-targeted therapeutic pipeline (TLX591-Tx, TLX597-Tx) and has first-mover advantage in the commercial radioligand therapy market.
  • GE HealthCare: GE HealthCare is a broad incumbent in molecular imaging, manufacturing PET scanners (including the GE FASTlab production platform used by Telix for Gozellix), radiopharmaceuticals, and contrast media. As a diversified imaging and diagnostics major, it overlaps with Telix across the imaging value chain.
  • Siemens Healthineers: Siemens Healthineers is a broad incumbent in medical imaging and radiation oncology (via Varian), with a strategic clinical collaboration announced with Telix in December 2025. It overlaps with Telix across PET imaging hardware, radiopharmacy, and radiation therapy—adjacent rather than direct competition.
  • Bayer: Bayer is a broad incumbent in radiopharmaceuticals with Xofigo (radium-223) for bone metastases in prostate cancer and an active radioligand therapy pipeline. Bayer competes with Telix in the prostate cancer theranostics space and is developing next-generation targeted radiopharmaceuticals.
  • Bracco Imaging: Bracco Imaging is a broad incumbent in diagnostic imaging agents and contrast media with a growing radiopharmaceutical portfolio. It competes with Telix in the broader molecular imaging market and has infrastructure for nuclear medicine distribution.

Direct peers

  • Curium: Curium is a global radiopharmaceutical manufacturer and distributor that competes directly with Telix in nuclear medicine imaging agents and operates a vertically integrated production and distribution model similar to Telix Manufacturing Solutions (TMS) and RLS Radiopharmacies.
  • Lantheus Holdings: Lantheus is a direct competitor in PSMA-PET imaging with Pylarify (piflufolastat F-18) approved for prostate cancer. Both companies target the same indication with similar radiopharmaceutical imaging agents and compete for hospital and urology clinic accounts in the U.S. and Europe.
  • ITM Isotope Technologies Munich: ITM is a direct peer in radioligand therapy with a pipeline of lutetium-177-based targeted radionuclide therapies for solid tumors. ITM also operates as a manufacturer of medical isotopes, competing with Telix on supply chain and pipeline assets in the radiopharmaceutical theranostics space.

Emerging players

  • Telix Pharmaceuticals (acquired by AstraZeneca: Fusion Pharmaceuticals): Fusion Pharmaceuticals (acquired by AstraZeneca) is an emerging player in targeted alpha therapies using actinium-225, directly comparable to Telix's TLX252 and TLX592 alpha-emitting programs. Both companies pursued radiopharmaceutical conjugates for solid tumors before their respective strategic transactions.

Others

  • Cardinal Health: Cardinal Health is a commercial radiopharmacy distribution partner (supplies finished unit doses of Gozellix to U.S. customers) and operates its own radiopharmaceutical distribution network. While primarily a logistics partner, it is an adjacent participant in the U.S. nuclear medicine supply chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Telix Pharmaceuticals social profiles

Digital presence

Telix Pharmaceuticals compliance and trust

Trust signal

Compliance10 records

Telix Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Telix Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles15 records

Telix Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Telix Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Telix Pharmaceuticals M&A and investment

M&A and investment

M&A12 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Telix Pharmaceuticals

What does Telix Pharmaceuticals do?

Telix Pharmaceuticals develops and commercializes therapeutic and diagnostic ("theranostic") radiopharmaceuticals for oncology and rare diseases. Its commercial core is the FDA-approved PSMA-PET imaging franchise of Illuccix and Gozellix (gallium-68 gozetotide kits for prostate cancer imaging), supported by Telix Manufacturing Solutions (TMS) and a late-stage pipeline of radioligand therapies (e.g., TLX591-Tx, TLX101-Tx, TLX250-Tx), imaging agents (Pixclara, Zircaix), the SENSEI drop-in gamma probe, and QDOSE dosimetry software.

Is Telix Pharmaceuticals a public or private company?

Telix Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Telix Pharmaceuticals founded?

Telix Pharmaceuticals was founded in 2015. It employs 1,001 to 5,000 people.

Where is Telix Pharmaceuticals based?

Telix Pharmaceuticals is headquartered in North Melbourne, Australia, in the Oceania region.

How does Telix Pharmaceuticals make money?

Five revenue lines are on record. Commercial product sales (Precision Medicine) is the primary driver. The others are third-party radiopharmacy distribution (RLS), strategic collaboration milestones and royalties, future therapeutic product sales (pipeline) and convertible bond financing.

Who are Telix Pharmaceuticals's main competitors?

Broad incumbents on record are Novartis, GE HealthCare, Siemens Healthineers, Bayer and Bracco Imaging. Direct peers are Curium, Lantheus Holdings and ITM Isotope Technologies Munich. Telix Pharmaceuticals (acquired by AstraZeneca: Fusion Pharmaceuticals) is listed as an emerging player. Cardinal Health is listed as an others.

Does Telix Pharmaceuticals have an API?

No public API is recorded for Telix Pharmaceuticals.

What industry is Telix Pharmaceuticals in?

Telix Pharmaceuticals's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaTelix Pharmaceuticals Limited (TLX) Presents at UBS Global Biopharma Conference 2026 TranscriptTelix Pharmaceuticals presented at UBS Global Biopharma Conference 2026, with CEO Christian Behrenbruch and CEO Richard Valeix. The company reported roughly $1 billion in revenue from its PSMA imaging business, which it said continues to grow. It also operates a therapeutics segment.Investing.comTelix at Bell Potter Healthcare Conference: growth, supply and pipelineTelix Pharmaceuticals outlined its growth strategy at the Bell Potter Healthcare Conference, projecting calendar 2026 revenue near $1 billion (AUD 1.4 billion) and a 33.5% year-on-year increase. The company highlighted the BiPASS trial, with data expected in Q1 2025, and Pixclara's commercial use with a favorable reimbursement code anticipated in Q1 2025.Yahoo3 Australian Growth Stocks With Revenue Growth Up To 52%Three Australian growth stocks—PDI Gold, Telix Pharmaceuticals, and Codan—are highlighted for revenue growth up to 52% and insider backing. PDI Gold's Kiniéro mine generates $156 million, Telix's imaging agents bring $803.8 million, and Codan's communications order book is $380 million. Future profitability depends on funding and cost trade-offs.Simply Wall StTelix Pharmaceuticals (ASX:TLX) Could Be 43% Undervalued Following Thera4Care Trial SelectionTelix Pharmaceuticals' FAP-targeting therapy TLX400-Tx was selected for a Phase 1 trial using terbium-161 in Europe's Thera4Care initiative. The stock trades at a discount to analyst targets, with fair value estimates of A$24.51 and A$29.81. The company faces risks from an SEC subpoena and pricing pressure in PSMA imaging.NasdaqTelix Targets $1.5 Bln Revenue In 2027 As ITM Deal May Accelerate Therapy Launch To 2027Telix Pharmaceuticals targets $1.5 billion in 2027 revenue, including its proposed $2.35 billion merger with ITM Isotope Technologies. The deal could accelerate ITM's first commercial therapeutic launch to 2027, with $50 million in synergies expected within two years. Telix also expects six approved products by 2027.PRESSBEETelix Joins Thera4Care with TLX400-Tx to Accelerate Translation of Next Generation FAP-Targeting Theranostics ...Middle EastTelix's FAP-targeting therapy candidate TLX400-Tx has been selected for evaluation with terbium-161 in the Thera4Care initiative, which aims to establish an integrated theranostics ecosystem to broaden patient access in Europe. The selection was based on clinical potential.The future of tradingTelix Joins Thera4Care for Phase 1 Trial of Terbium-161 FAP-Targeting Cancer TherapyTelix Pharmaceuticals joined Thera4Care to evaluate a terbium-161 version of its FAP-targeting therapy candidate in a Phase 1 clinical trial. The study will assess safety and preliminary activity in metastatic solid tumors, initially focusing on ovarian cancer, pancreatic cancer, and sarcomas. Results are expected to inform development of TLX400-Tx, which uses lutetium-177.MarketBeatTelix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy PushTelix Pharmaceuticals outlined its commercial strategy and late-stage radiopharmaceutical pipeline at an investor event, targeting $1.5 billion in revenue next year. The company expects revenue of roughly $1 billion this year and anticipates finishing at the top end of its guidance. It plans to accelerate its therapeutic radiopharmaceutical launch from 2028 to 2027 via an ITM deal.YahooAustralian Growth Stocks With Insider Buying For October 2026Three Australian growth stocks with high insider ownership are highlighted: Regis Healthcare, Liontown, and Telix Pharmaceuticals. Regis Healthcare generates A$1.35b from aged care, Liontown reports A$639m from mineral exploration, and Telix Pharmaceuticals has $803.8m in imaging revenue. The article notes each faces margin or pipeline inflection risks.Simply Wall St3 Australian Growth Stocks With Up To 34% Earnings GrowthThree Australian growth stocks—Liontown, Telix Pharmaceuticals, and Codan—are highlighted for high insider ownership and earnings growth. Liontown earns A$639m from lithium exploration, Telix generates $704m from imaging agents, and Codan reports A$506m from communications. Each faces cost or funding pressures that could affect margin durability.